Acalabrutinib
Oral, twice daily, indefinitely
Acalabrutinib + Obinutuzumab
Chemotherapy + Rituximab
Intravenous, monthly, 6 months
Ibrutinib
Oral, once daily, indefinitely
Venetoclax + Obintuzumab
Oral, once daily, 12 months
IV infusion monthly x 6
Zanubrutinib
Cure
No CLL, Normal life
Complete Remission
Normal CBC, No nodes/spleen
Overall Response
Overall Survival
Live Longer ± Remission
Progression-free Survival
Live Longer in Remission
Atrial fibrillation/flutter
Bleeding
Bruising, internal bleeding
Hypertension
Requires treatment
Infection
Decreased blood counts
Infusion Reaction
Neutropenia
Thrombocytopenia
Tumor Lysis
Rapid cell death -> kidney injury
HARMS
ACCEPTABLE
 HARMS
LEAST ACCEPTABLE
BENEFITS
LEAST IMPORTANT
MOST IMPORTANT

Harms Salience

All Available Harms
Atrial fibrillation/flutter
Bleeding
Hypertension
Infection
Infusion Reaction
Neutropenia
Thrombocytopenia
Tumor Lysis
Harms
Likelihood
Severity

Benefits Salience

All Available Benefits
Cure
Complete Remission
Overall Response
Overall Survival
Progression-free Survival
Benefits
Likelihood
Desirability